BackLandos Biopharma Overview

Landos Biopharma Long Term Debt

Landos Biopharma's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

Landos Biopharma Long Term Debt History

Loading

Landos Biopharma vs. peers: Long Term Debt Comparison

Loading

Landos Biopharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Landos Biopharma (LABP) FAQ

As of the most recent data (March 2024), LABP shows a long-term debt of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LABP's long-term debt is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Landos Biopharma is outperforming or lagging.

Tracking LABP's long-term debt over time shows whether Landos Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Landos Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Landos Biopharma's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.